As a medical oncologist and the leader of Memorial Sloan Kettering’s Division of Solid Tumors, I have two principal responsibilities: to manage gynecologic malignancies (predominantly ovarian cancers) and to lead our program in early drug development.
A critical role of medical oncologists is to coordinate surgery, radiation oncology treatments, and chemotherapy to help people preserve their quality of life during treatment. Since joining Memorial Sloan Kettering in 1993 I have had the privilege of caring for thousands of patients with solid tumors and finding the management approach that works best for them.
One of the most rewarding parts of my career has been the long-term relationships that I have developed with these individuals and their families. I am also deeply committed to providing continuity of care for my patients, from earliest diagnosis through multiple treatments into the supportive care phase of cancer management.
For women with early-stage gynecologic cancers, we offer aggressive treatments with the goal of curing the cancer. Managing the toxic effects of these therapies is crucial—but cure is often possible. When a cure is much less likely because the cancer is more advanced, we focus primarily on controlling the cancer and taking steps to preserve the woman’s quality of life. We also offer new, investigational therapies to people with cancer that has recurred (reappeared).
In addition to the daily care of women with gynecologic cancers, I run clinical trials that are testing new, targeted drugs, and oversee a small research laboratory looking for answers to such questions as why certain tumors resist drug treatment and how genes can affect the development of tumors.
In my work on a national scale, I serve on committees for the National Cancer Institute and play a role on the editorial boards of such publications as Investigational New Drugs, Gynecologic Oncology, and Clinical Cancer Research. Currently I am the associate editor of the Journal of Clinical Oncology. Over the years, I have authored (or co-authored) more than 150 journal articles on such topics as ovarian cancer biology and the results of clinical investigations, from the earliest stages of drug development to randomized phase III trials.
- Clinical Expertise: Gynecologic Oncology; Clinical Pharmacology; General Medical Oncology
- Languages Spoken: English
- Education: MD, University of Wisconsin School of Medicine
- Residencies: Presbyterian Hospital (New York); The New York Hospital/Cornell Medical Center
- Fellowships: Harvard Medical School; Dana-Farber Cancer Institute; Brigham and Women's Hospital
- Board Certifications: Medical Oncology; Internal Medicine
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Co-Investigated by David R. Spriggs
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more